A short-term evaluation of a prototype  disposable oscillating positive expiratory  pressure (OPEP) device in a cohort of children  with cystic fibrosis by O'Sullivan, Kevin Jeremiah et al.
O’Sullivan et al. BMC Pulm Med          (2021) 21:158  
https://doi.org/10.1186/s12890-021-01525-3
RESEARCH
A short-term evaluation of a prototype 
disposable Oscillating Positive Expiratory 
Pressure (OPEP) device in a cohort of children 
with cystic fibrosis
Kevin J. O’Sullivan1,2, Valerie Power1, Barry Linnane2,3,4, Deirdre McGrath2,3, Magdalena Mulligan2,5, 
Rebecca White5, Leonard W. O’Sullivan1 and Colum P. Dunne2* 
Abstract 
Background: Oscillating Positive Expiratory Pressure (OPEP) devices are important adjuncts to airway clearance 
therapy in patients with cystic fibrosis (CF). Current devices are typically reusable and require daily, or often more 
frequent, cleaning to prevent risk of infection by acting as reservoirs of potentially pathogenic organisms. In response, 
a daily disposable OPEP device, the UL-OPEP, was developed to mitigate the risk of contamination and eliminate the 
burdensome need for cleaning devices.
Methods: A convenience sample of 36 participants, all current OPEP device users, was recruited from a paediatric CF 
service. For one month, participants replaced their current OPEP device with a novel daily disposable device. Assess-
ment included pre- and post-intervention lung function by spirometry, as well as Lung Clearance Index. Quality of life 
was assessed using the Cystic Fibrosis Questionnaire – Revised, while user experience was evaluated with a post-study 
survey.
Results: 31 participants completed the study: 18 males; median age 10 years, range 4–16 years. Lung function (mean 
difference ± SD, %FEV1 = 1.69 ± 11.93; %FVC = 0.58 ± 10.04; FEV1: FVC = 0.01 ± 0.09), LCI (mean difference ± SD, 
0.08 ± 1.13), six-minute walk test, and CFQ-R were unchanged post-intervention. Participant-reported experiences of 
the device were predominantly positive.
Conclusions: The disposable OPEP device maintained patients’ lung function during short term use (≤ 1 month), and 
was the subject of positive feedback regarding functionality while reducing the risk of airway contamination associ-
ated with ineffective cleaning.
Registration: The study was approved as a Clinical Investigation by the Irish Health Products Regulatory Authority 
(CRN-2209025-CI0085).
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Background
Cystic Fibrosis (CF) is an inherited life-limiting disorder 
that is characterised by thickened, dehydrated pulmo-
nary secretions, and ineffective mucociliary clearance. 
As a result, microorganisms are not effectively removed 
from the airways [1, 2]. This initiates a repetitive cycle of 
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chronic infection, inflammation, and leads typically to 
bronchiectasis and progressive obstructive airway dis-
ease [1]. Airway clearance is therefore a fundamental part 
of managing patients with CF [2]. The purported benefits 
of airway clearance were first described in The Lancet in 
1901 [3], while commercial devices to aid chest physio-
therapy in children with CF began to appear in the 1970s 
[4].
Positive Expiratory Pressure (PEP) therapy was devel-
oped to promote mucus clearance by splinting open 
collapsed airways [5] and by increasing intrathoracic 
pressure distal to mucus plugging through collateral ven-
tilation via the canals of Lambert and pores of Kohn [6]. 
PEP therapy is achieved by blowing against a fixed or 
variable small-exit orifice, which increases pressure by 
limiting flow. The target “therapeutic range” expiratory 
pressure is detailed in the literature as 10–20 cm  H2O [6].
Oscillating Positive Expiratory Pressure (OPEP) ther-
apy was a further development in airway clearance ther-
apy, which has been shown to be at least as effective as 
traditional chest physiotherapy for mobilising secretions 
[7, 8]. Oscillating intrapulmonary pressure acts to reduce 
the viscoelastic properties of the secretions, while short 
increases in expiratory flow act to mobilise secretions 
cephalad [6, 9].
Numerous PEP and OPEP devices are commercially 
available today, with varying levels of associated device-
specific complexity, resistance settings, and usability. 
These devices, however, require regular cleaning to avoid 
contamination with pathogens exhaled into the device or 
transferred by contact with the mouthpiece. Contamina-
tion of respiratory devices in CF care is well documented 
[10–12]. Arising thereof there is a heavy burden on 
patients and their care givers to manage infection con-
trol risks. Common CF pathogens include Staphylococ-
cus aureus, Pseudomonas aeruginosa, Stenotrophomonas 
maltophilia and Burkholderia cepacia [13]. A 2017 study 
by Manor et al. found most airway clearance devices were 
contaminated after routine use (28/30 devices). After 
cleaning by the users, only 50% of devices had undergone 
complete eradication of those microbes, 30% showed 
partial eradication, and failure was observed in 13% [10]. 
Cleaning procedures for OPEP devices that are provided 
by their manufacturers are often divergent from the pub-
lished guidance of organisations such as the CF Founda-
tion (CFF). For example, some instructions recommend a 
final step of rinsing the device with tap water, which has 
been found to be a potential source of pathogenic organ-
isms, whereas the CFF recommends rinsing with sterile 
water [12, 14]. This is of particular concern in situations 
where it is not practical or feasible for patients or their 
care givers to perform these cleaning routines, such as 
during in-patient antimicrobial treatment.
In response to these issues, a novel daily-disposable 
device was developed in the University of Limerick to 
eliminate the infection risk associated with contamina-
tion and ineffective cleaning (the “UL-OPEP”, Fig.  1—
Left). Figure  1—Middle, shows the device in use by a 
paediatric subject. Figure  1—Right illustrates how the 
device functions. As the patient exhales into the mouth-
piece of the device (A), the fixed orifice (B) restricts 
expiratory flow to generate a mean increase in intrapul-
monary pressure. The expiratory flow exiting the orifice 
causes the polymer ball (C) to revolve around the annular 
track (D). This causes the polymer ball (C) to periodically 
block the orifice, momentarily increasing intrapulmonary 
pressure to generate oscillations.
The purpose of the current study was to evaluate use 
of the UL-OPEP device in practice by children with CF 
over a short-term course of one month, and to determine 
its effectiveness compared to the current standard of 
care (i.e., use of existing OPEP devices). As part of this, 
Fig. 1 UL-OPEP device
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we also report current device use and cleaning regimens, 
lung function, Cystic Fibrosis Questionnaire Revised, and 
usability data for the new disposable device.
Methods
A cohort of 36 participants was recruited from the pae-
diatric CF service in University Hospital Limerick (UHL) 
in the mid-west of Ireland, where incidence of CF is high-
est globally [15]. Potential participants attending regular 
clinic visits were identified by the clinical staff as current 
users of at least one hand-held OPEP device and being 
compliant with OPEP therapy. These potential partici-
pants were invited by post to participate in the study, 
were provided information about the study, and were 
followed up with a telephone call (two weeks later) to 
formally complete the recruitment process including 
consenting formally to participate. Subsequently, they 
attended scheduled clinics.
A single sample pre-/post-intervention study design 
was employed, with evaluations and measurements com-
pleted in the paediatric CF unit, UHL. All participants 
were trained by their specialist respiratory physiothera-
pist to use the UL-OPEP device at the first clinic visit. 
Each participant was instructed to directly replace their 
current primary OPEP device with the UL-OPEP device 
– no change to frequency or duration of therapy was 
advised. If more than one OPEP device was used regu-
larly by a participant, they were instructed to continue 
using additional devices as per their current standard of 
care.
Each participant was then provided with a pack con-
taining 30 UL-OPEP disposable devices (one for each day 
of the study), instructions for use, and a patient informa-
tion leaflet.
Specifically, pre- and post-intervention lung function 
was assessed by a CF specialist physiotherapist using 
the EasyOne Air Spirometer (NDD Medzintechnik AG, 
Switzerland) interpreted according to Global Lung Func-
tion Initiative 2012 predicted values [16]. Routine meas-
urements of Forced Expiratory Volume in one second 
 (FEV1, litres) and Forced Vital Capacity (FVC, litres), 
 FEV1 and FVC Predicted (%) [16], and  FEV1/FVC ratio 
were collected. Lung Clearance Index (LCI) was assessed 
via multiple-breath nitrogen washout (Exhalyser D, Eco 
Medics, Switzerland). A six-minute walk test (6MWT) 
was performed pre- and post-study as a simple and 
reproducible test of exercise tolerance for children and 
adolescents with CF [17]. The Cystic Fibrosis Question-
naire – Revised (CFQ-R) was used to measure health-
related quality of life across several domains from the 
patient’s and/or parent’s perspective [18–20]. The appro-
priate CFQ-R version was administered according to the 
age of the participant; CFQ-R Child (6–13 years), and the 
paired CFQ-R Parent, or CFQ-R Teen/Adult (≥ 14 years). 
The CFQ-R is scored on a 0–100 scale, with higher scores 
indicating better health-related quality of life.
A pre-intervention questionnaire recorded the patients’ 
current OPEP device(s) and associated routines used by 
each participant, as well as: cleaning methods; clean-
ing frequency; length of time to clean; and any concerns 
about cleanliness of reusable devices. User experience of 
the UL-OPEP device was evaluated with a post-interven-
tion questionnaire, rated on five-point Likert scales (from 
strongly agree to strongly disagree).
All data were tabulated in Microsoft Excel, and ana-
lysed in SPSS Version 26 (IBM, New York, USA). Paired 
sample t-tests were used to evaluated Pre- and Post- 
study results.
The study was conducted in compliance with the Good 
Clinical Practices protocol and the Declaration of Hel-
sinki principle. Approval for this study was granted by the 
UHL Ethics Board, September 2018. The study was also 
approved as a Clinical Investigation by the Irish Health 
Products Regulatory Authority (CRN-2209025-CI0085). 
Informed consent was obtained from parents/guardians 
prior to commencement of the study.
Results
In total 31 participants completed the study: 13 female 
and 18 male; median age 10 years, range 4–16 years. Of 
the study cohort, 65% (n = 20) had the homozygous Delta 
F508 mutation, 29% (n = 9) the heterozygous Delta F508 
mutation, and 6% (n = 2) other (G551D/621 + 1G > T, 
G27X/2622 + 1G > A). Table  1 details summary demo-
graphic information regarding participants’ heights and 
weights as interpreted, in accordance with CDC guid-
ance [21], with data from the Royal College of Paediat-
rics and Child Health (RCPCH). This is a combination of 
the Neonatal and Infant Close Monitoring Growth Chart 
(NICM), the UK WHO 0–4 years growth chart, and the 
RCPCH UK Growth chart [2–18], and reports lung func-
tion as interpreted by the Global Lung Function Initiative 
2012 predicted values [16]. Five participants withdrew 
from the study, one due to unrelated clinical reasons and 
four due to unrelated personal circumstances.
Participants used a variety of PEP/OPEP devices prior 
to the study. Twenty four used an Aerobika (Trudell, 
Ontario, Canada), five PEP/RMT (Smiths Medical, NH, 
USA), five Thera-Pep (Wellspect Healthcare, Molndal, 
Sweden), and one ‘Bubble Pep’ (i.e. blowing bubbles in 
a basin). Four used multiple devices. No participants 
reported using other adjunct therapies such as manual 
percussion, high-frequency chest wall compression, or 
intrapulmonary percussive ventilation.
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There was no significant difference in the scores 
for FEV1 (Litres) Pre- (x̄ = 1.95, SD = 0.90) and Post- 
(x̄ = 1.98, SD = 0.87) study; t(29) = −0.840, p = 0.408 or, 
FVC (Litres) Pre- (x̄ = 2.48, SD = 1.12) and Post- (x̄ = 2.52, 
SD = 1.16) study; t(29) = −0.855, p = 0.400 (Fig. 2). FEV1/
FVC Ratio Pre- (x̄ = 0.79, SD = 0.11) and Post- (x̄ = 0.79, 
SD = 0.10) study; t(29) = −0.449, p = 0.656 (Fig. 3). Lung 
Clearance Index Pre- (x̄ = 9.58, SD = 2.29) and Post- 
(x̄ = 9.66, SD = 2.10) study; t(27) = −0.369, p = 0.715 
(Fig.  4). 6MWT (meters) Pre- (x̄ = 510.21, SD = 78.59) 
and Post- (x̄ = 515.03, SD = 86.75) study; t(27) = −0.359, 
p = 0.723 (Fig.  5). 6MWT (SpO2 Avg.) Pre- (x̄ = 96.07, 
SD = 2.38) and Post- (x̄ = 96.53, SD = 2.78) study; 
t(27) = −0.826, p = 0.416. And, 6MWT (SpO2 1st Min-
ute) Pre- (x̄ = 93.28, SD = 4.25) and Post- (x̄ = 94.39, 
SD = 4.07) study; t(27) = −1.197, p = 0.242. For all box-
whisker plots in Figs. 2, 3, 4 and 5, the mean (x), median 
(horizontal line), interquartile ranges, and outliers (if 
Table 1 Baseline characteristics of the study cohort
Height Weight
[Cm] [% Predicted] [z score] [Kg] [% Predicted] [z score]
Average (SD) 143.4 (17.2) 48.9 −0.035 41.1 (15.0) 61.2 0.425
Minimum 106.0 < 0.4 −3.148 18.2 8.0 −1.404
Maximum 175.0 > 99.6 2.637 76.8 > 99.6 3.310
Median 146.0 48.0 −0.052 39.4 65.0 0.378
FEV1 FVC FEV1/FVC
[Litres] [% Predicted] [Litres] [% Predicted] [Ratio] [% Predicted]
Average (SD) 1.89 (0.85) 79.37 2.41 (1.05) 91.56 0.787 88.91
Minimum 0.7 10 0.96 55 0.52 60.5
Maximum 4.02 114 5.43 121 0.981 109.7
Median 1.6 83 2.14 92 0.804 90
Fig. 2 FEV1 and FVC (% predicted) pre- and post-study (Bars = IQR) Fig. 3 FEV1/FVC Ratio pre- and post-study (Bars = IQR)
Fig. 4 Lung Clearance Index values pre- and post-study (Bars = IQR)
Page 5 of 9O’Sullivan et al. BMC Pulm Med          (2021) 21:158  
present) are shown. Table 2 details the frequency of use, 
duration of use, cleaning frequency, cleaning methods, 
cleaning duration, and storage habits of the participants.
Participants were also asked whether they were ever 
concerned about the cleanliness of their OPEP devices, 
to which 24% answered never, 6% rarely, 32% sometimes, 
and 38% often.
The participant scores at baseline and follow-up for the 
CFQ-R domains common to both the Child and Teen/
Adult versions are presented in Table  3. No significant 
differences in changes were observed (paired sample 
t-tests, all p > 0.05) in scores pre- and post- study across 
the dimensions for the participants.
From the post-intervention device questionnaire, most 
participants felt that the UL-OPEP device was easy to use 
(72% Strongly Agree; 24% Agree; 4% Neutral), addressed 
issues they had with cleaning their current OPEP device 
(72% Strongly Agree; 16% Agree; 12% Neutral), and 
encouraged them to perform their OPEP therapy more 
regularly (52% Strongly Agree; 28% Agree; 16% Neu-
tral, 4% Strongly Disagree). All participants agreed that 
they would like to use the UL-OPEP as their usual OPEP 
device (76% Strongly Agree; 24% Agree) (Fig. 6).
Discussion
This study evaluated the performance of a novel daily 
use OPEP device over the course of one month in chil-
dren with CF. In summary, the outcomes indicate that 
despite its small form, the device performed as well as 
participants’ existing OPEP devices as an adjunct to air-
way clearance, with no adverse events recorded during 
or after the study. There was no deterioration in partici-
pants’ health as determined via spirometry, LCI, 6MWT, 
and health related quality of life measurement. Although 
the study was of short duration, participants expressed a 
clear preference for the continued use of the UL-OPEP 
over their existing device. Notably, there was consider-
able reduction in time spent dissembling, cleaning, dry-
ing, and re-assembling devices daily, and a high level of 
confidence regarding cleanliness of the UL-OPEP device.
Spirometry results indicate that lung function varied 
greatly across our sample, yet relative changes in pre-
dicted spirometry values observed pre- and post-study 
were largely within the bounds of normal variability of 
these measures. For example, up to a 12% relative change 
in intra-subject  FEV1 may be considered normal variabil-
ity for short-term assessment such as the present study 
[22].
LCI values were higher than previously reported upper 
limits of normality [23] for 94% of our measurements at 
baseline, and for 89% at follow-up, despite a large propor-
tion of our participants providing normal or close to nor-
mal spirometry results. This may be explained by the fact 
that LCI is a more sensitive early indicator of peripheral 
airway disease in children with CF than spirometry [24, 
25]. Changes in LCI observed post-intervention are likely 
due to normal variability, since up to 17–25% variability 
can be expected in clinically stable school-age children 
with CF [26, 27].
The 6MWT results indicated that exercise tolerance 
and functional capacity were unchanged following adop-
tion of the UL-OPEP [28] although, as expected, six-min-
ute walk distance was lower in our sample than reference 
values for healthy children in the same age range [29].
Changes in all domains within the CFQ-R from pre- to 
post-study were minimal, and highly variable, indicat-
ing that no consistent clinically important changes were 
observed during the study period. Scores indicate that 
health-related quality of life across all CFQ-R domains 
was largely high, but also variable among the sample.
The post-intervention feedback from participants and 
their parents/guardians regarding the new device was 
overwhelmingly positive. In particular, all participants 
agreed that the UL-OPEP was easy to learn to use; pre-
ferred the small size of the device to the size of their 
existing devices; and stated a preference for use the new 
device as their usual OPEP device, if available to them. 
The fact that it is both easy to learn how to use initially, 
and easy & convenient to use generally is of considerable 
importance since poor performance of OPEP therapy is 
common among children and adolescents with CF [30].
The results of this study also demonstrate notable 
variance in frequency of use, duration of use, cleaning 
regimes and storage of OPEP devices amongst children 
with CF despite regular standardised education from 
their specialist physiotherapists. Thus, there is a need to 
develop devices and related strategies that simplify and 
Fig. 5 Six Minute Walk Test results (metres) pre- and post-study 
(Bars = IQR)
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reduce the patient/care giver burden associated with air-
way clearance therapy.
Limitations
This is the first study evaluating this prototype dispos-
able OPEP device. While acknowledging the limited 
sample size in the study, the study design was based on 
previous registered clinical trials where short term stud-
ies of OPEP devices were conducted for period of up to 
four weeks [31, 32]. In the context of this relatively brief 
duration, results are not over-stated and the conclusions 
drawn are modest, albeit promising. A larger, longer 
duration study would be required to enable generalisa-
tion of results to the wider CF patient population.
It is acknowledged that long-term use of a daily dis-
posable OPEP device would most likely increase costs 
compared to current offerings. The UL-OPEP is not cur-
rently commercially available and so actual cost-in-use 
figures, which would be based on large-scale manufac-
ture and distribution models, are unknown. However, it 
Table 2 Results of usage, cleaning, and storage habits of current OPEP devices
Frequency of use %
Occasional (only when unwell) 11
Infrequent (2–3 times per week) 14
Once a day 25
Twice a day 44
Three or more times per day 6
Cleaning frequency %
After each use 53
Daily 17
Every second day 6
Twice a week 5
Weekly 11
Bi-weekly 3
Not at all 5
Duration of cleaning %




More than 20 min 27
Duration of use %
Less than 5 min 6
5–10 min 47
More than 10 min 25
Number of breaths performed 22
Methods of cleaning %
Hand wash 50
Steriliser 15
Handwash + steriliser 32
Dishwasher 3
Storage habits %
Open un-protected (countertop/windowsill) 24
Open protected (cupboard/drawer) 18
Sealed container (plastic box/bag) 46
Non-sealed container (soft case) 12
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is reasonable to speculate that the cost of routine or long-
term daily use may limit accessibility unless supported 
by local health care systems or health insurance. Despite 
this, the potential benefits of employing a cost-effective 
disposable device for short term specific-purpose use 
such as travel, clinic evaluations, and in-patient stays are 
attractive.
Conclusions
Our findings demonstrate that the novel daily disposable 
device has equivalent performance to currently available 
OPEP devices in practice, at least over a relatively short 
period of one month, with no risk of contamination or 
infection due to ineffective cleaning regimes that are no 
longer required. Participants reported a preference for 
the new device over their existing OPEP devices due to 
ease of use, convenience, and efficacy it provided. There-
fore, it may be a useful adjunct to aid airway clearance 
in children with CF and may promote greater adherence 
and compliance to airway clearance.
In the context of the current coronavirus pandemic, a 
disposable respiratory device appears both relevant and 
prudent, especially for patient with respiratory condi-
tions or susceptibility to infection for whom hospital 
stays may be relatively frequent and unavoidable.
Table 3 CFQ-R Pre- and Post-study scores
CFQ-R domain Baseline, mean (SD) Follow-up, mean (SD) Change, mean (SD)
Physical 85.9 (18.6) 84.7 (21.2) −1.2 (20.4)
Emotion 80.0 (12.4) 80.1 (15.1) 0.1 (8.9)
Social 78.5 (17.0) 79.4 (18.0) 0.9 (13.6)
Body image 79.6 (23.7) 83.3 (14.7) 3.8 (20.0)
Eating 91.1 (15.4) 88.0 (16.6) −3.1 (13.4)
Treatment burden 81.8 (20.8) 82.2 (18.4) 0.5 (12.6)
Respiratory symptoms 80.1 (17.3) 77.1 (18.9) −3.0 (18.0)
Digestive symptoms 82.0 (19.9) 74.1 (24.0) −7.9 (27.9)
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
UL-OPEP is easy to use
UL-OPEP is more convenient than my current device
Using UL-OPEP saves me me each day
It was easy to learn how to use UL-OPEP
UL-OPEP is as effecve as my current OPEP device
UL-OPEP addresses issues I have with cleaning my…
UL-OPEP addresses concerns I have about the…
UL-OPEP encourages me to perform my OPEP therapy…
I prefer the size of UL-OPEP to the size of my current…
UL-OPEP is beer than my current OPEP device
I would like to use UL-OPEP as my usual OPEP device
Strongly Agree Agree Neutral Disagree Strongly Disagree
Fig. 6 Subjective evluation of usability aspects of the UL OPEP device post study
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